Mycobacterial protein targets

Mycobacterial protein targets modeled in tuberculosis inhibitor studies refers to a broad classification of essential proteins within Mycobacterium tuberculosis (Mtb) that serve as the primary focus for drug discovery and computational modeling efforts (Naran et al., 2022). These targets are involved in critical survival pathways, most notably the synthesis of the unique mycobacterial cell wall, which includes enzymes like InhA (enoyl-ACP reductase) and DprE1 (decaprenylphosphoryl-beta-D-ribose 2'-epimerase) (Vilchèze & Jacobs, 2014; Makarov et al., 2009). Other key targets include the transcriptional machinery (RpoB), energy metabolism components (ATP synthase), and protein synthesis apparatus (Gygli et al., 2017). Because this term represents a diverse group of molecules rather than a single receptor or enzyme, it is typically used in the context of high-throughput screening or structure-based drug design (SBDD) to describe the collective landscape of Mtb vulnerabilities. Drugs targeting these proteins, such as isoniazid, rifampicin, and bedaquiline, are the cornerstones of tuberculosis therapy, though the emergence of multi-drug resistant (MDR) strains necessitates the ongoing modeling of novel inhibitors against these and emerging targets (Andries et al., 2005).

Other names

Mycobacterium tuberculosis drug targetsAntitubercular protein targetsM. tuberculosis proteome targets

Inhibition of essential mycobacterial processes including mycolic acid synthesis (InhA), RNA transcription (RpoB), ATP production (AtpE), and cell wall arabinan synthesis (EmbB).